Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Therma Bright Yönetim

Yönetim kriter kontrolleri 1/4

We currently do not have sufficient information about the CEO.

Anahtar bilgiler

Rob Fia

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	8.4yrs
CEO sahipliği	7.1%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	6.7yrs

Son yönetim güncellemeleri

Recent updates

Is Therma Bright (CVE:THRM) In A Good Position To Invest In Growth?

Nov 02

We Think Therma Bright (CVE:THRM) Can Afford To Drive Business Growth

Jul 04

CEO Tazminat Analizi

Rob Fia'un ücretlendirmesi Therma Bright'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Apr 30 2024	n/a	n/a	-CA$3m
Jan 31 2024	n/a	n/a	-CA$3m
Oct 31 2023	n/a	n/a	-CA$3m
Jul 31 2023	n/a	n/a	-CA$4m
Apr 30 2023	n/a	n/a	-CA$3m
Jan 31 2023	n/a	n/a	-CA$3m
Oct 31 2022	n/a	n/a	-CA$4m
Jul 31 2022	CA$733k	CA$125k	-CA$6m
Apr 30 2022	n/a	n/a	-CA$6m
Jan 31 2022	n/a	n/a	-CA$7m
Oct 31 2021	n/a	n/a	-CA$8m
Jul 31 2021	CA$600k	CA$125k	-CA$9m
Apr 30 2021	n/a	n/a	-CA$8m
Jan 31 2021	n/a	n/a	-CA$6m
Oct 31 2020	n/a	n/a	-CA$4m
Jul 31 2020	CA$53k	CA$53k	-CA$627k
Apr 30 2020	n/a	n/a	CA$158k
Jan 31 2020	n/a	n/a	CA$10k
Oct 31 2019	n/a	n/a	-CA$260k
Jul 31 2019	CA$15k	CA$15k	-CA$422k
Apr 30 2019	n/a	n/a	-CA$1m
Jan 31 2019	n/a	n/a	-CA$1m
Oct 31 2018	n/a	n/a	-CA$1m
Jul 31 2018	CA$30k	CA$30k	-CA$1m

Tazminat ve Piyasa: Insufficient data to establish whether Rob's total compensation is reasonable compared to companies of similar size in the Canadian market.

Tazminat ve Kazançlar: Rob's compensation has increased whilst the company is unprofitable.

CEO

Rob Fia (54 yo)

8.4yrs

Görev süresi

CA$732,500

Tazminat

Mr. Roberto Fia, also known as Rob, CFA, serves as the Chairman and President of Therma Bright Inc. (formerly known as The Jenex Corporation) and has been its Chief Executive Officer since May 18, 2016. Mr...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Roberto Fia	Chairman	15.1yrs	CA$732.50k	7.07% CA$ 1.8m
Bruno Maruzzo	Member of Advisory Board	6.4yrs	Veri yok	Veri yok
Gilbert Sharpe	Member of Advisory Board	6.6yrs	Veri yok	Veri yok
Andrew Peterson	Independent Director	6.8yrs	Veri yok	0.26% CA$ 69.0k
Douglas Sommerville	Member of Advisory Board	less than a year	Veri yok	Veri yok
Sungbum Huh	Independent Director	6.3yrs	Veri yok	Veri yok
Joseph Heng	Independent Director	8.4yrs	Veri yok	Veri yok
Stephen McNeill	Member of Advisory Board	6.8yrs	Veri yok	Veri yok
Leonidas Notidis	Member of Advisory Board	6.8yrs	Veri yok	Veri yok
Michael Bosman	Member of Advisory Board	6.8yrs	Veri yok	Veri yok
Steven Bennett	Member of Advisory Board	6.4yrs	Veri yok	Veri yok
Too Min	Member of Advisory Board	6.1yrs	Veri yok	Veri yok

6.7yrs

Ortalama Görev Süresi

72yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: THRM's board of directors are considered experienced (6.7 years average tenure).

Therma Bright Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Therma Bright Inc. Appoints Douglas S. Sommerville to Its Advisory Board

Insufficient new directors

Therma Bright Inc., Annual General Meeting, Dec 18, 2023

Insufficient new directors

Therma Bright Inc., Annual General Meeting, Jun 17, 2022

Independent Director recently sold CA$255k worth of stock

Recent updates

Therma Bright Inc. announced that it expects to receive CAD 3 million in funding

Therma Bright Inc. announced that it expects to receive CAD 0.4045 million in funding

Therma Bright Inc. Appoints Douglas S. Sommerville to Its Advisory Board

Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 3Q 2023)

Therma Bright Inc. announced that it has received CAD 1 million in funding

New major risk - Shareholder dilution

Therma Bright Inc. announced that it expects to receive CAD 1 million in funding

Second quarter 2024 earnings released: EPS: CA$0 (vs CA$0.003 loss in 2Q 2023)

Insufficient new directors

Therma Bright Inc., Annual General Meeting, Dec 18, 2023

New major risk - Share price stability

Third quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2022)

Therma Bright Inc. and Inretio Inc. Announces Successful Completion of Good Laboratory Practice Study for Its Breakthrough Preva™? Mechanical Thrombectomy Device

Second quarter 2023 earnings released: CA$0.003 loss per share (vs CA$0.005 loss in 2Q 2022)

Full year 2022 earnings released: CA$0.026 loss per share (vs CA$0.043 loss in FY 2021)

Insufficient new directors

Is Therma Bright (CVE:THRM) In A Good Position To Invest In Growth?

Therma Bright Inc. Provides Update on FDA EUA Review Process

Therma Bright Inc. Provides Updates on Applications for Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test

We Think Therma Bright (CVE:THRM) Can Afford To Drive Business Growth

Third quarter 2022 earnings released: CA$0.005 loss per share (vs CA$0.011 loss in 3Q 2021)

Therma Bright Submits Health Canada Application for Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test for Point-of-Care (POC)

Therma Bright Inc. Provides Update on FDA EUA Application Process for Acuvid(TM) Covid-19 Rapid Antigen Saliva Test

Therma Bright to Submit Application to Health Canada for Approval of its AcuVid COVID-19 Rapid Antigen Saliva Test

Therma Bright Inc., Annual General Meeting, Jun 17, 2022

Second quarter 2022 earnings released: CA$0.005 loss per share (vs CA$0.008 loss in 2Q 2021)

Therma Bright Inc. announced that it has received CAD 6 million in funding

Therma Bright Inc. announced that it expects to receive CAD 6 million in funding

Therma Bright's AcuVid(TM) U.S. Clinical Performance Study Successfully Exceeds U.S. Food & Drug Administration's Emergency Use Authorization Requirements

Therma Bright Inc. Completes U.S. Clinical Performance Study Subject Recruitment

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Therma Bright Inc. to Test AcuVidTM on the Highly Contagious COVID-19 Delta Variant; Completes Brazilian Clinical Study for Final FDA EUA Submission

Therma Bright Inc. Provides an Update on the Exceptional Performance of Its AcuVidTM COVID-19 Rapid Antigen Saliva Test's Brazilian Clinical Study

Therma Bright Inc. Provides Update on its Brazilian Clinical Study of its Innovative 15- Minute COVID-19 Antigen Saliva Test

Therma Bright Inc. Initiates Clinical Performance Study in Brazil for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test

Therma Bright Inc. Submits Application to Research Ethics Board for Approval of Clinical Trials for AcuVid (TM) Covid-19 Rapid Saliva- Based Antigen Test

Therma Bright Enters into Clinical Trial Agreement for Its Acuvid(Tm) Covid-19 Rapid Saliva-Based Antigen Test

Independent Director recently sold CA$255k worth of stock

Therma Bright Inc. Reports Improved Accuracy for Covid-19 Rapid Saliva Antigen Test, CoviSafe, and Prepares for Prospective Studies

Therma Bright Inc. Appoints Ian Levine to the Advisory Board

New 90-day high: CA$0.35

First quarter 2021 earnings released: CA$0.018 loss per share

Chairman exercised options to buy CA$248k worth of stock.

New 90-day high: CA$0.28

Full year 2020 earnings released: CA$0.004 loss per share

Therma Bright Inc. (TSXV:THRM) completed the acquisition of assets of Saringer Life Science Technologies Inc. for CAD 0.43 million.

Therma Bright Inc. announced that it has received CAD 1.25 million in funding

New 90-day high - CA$0.30

Therma Bright Inc. announced that it expects to receive CAD 1 million in funding

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş